133 results
8-K/A
EX-10.1
neb ykirbna7p8vjyae
2 Feb 24
Departure of Directors or Certain Officers
4:49pm
8-K
1k3gni2x2xphl4v0u96
19 Jan 24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
5:14pm
8-K
EX-99.1
7uam5z 2ckln
19 Jan 24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
5:14pm
424B5
9ar30nkmc mdl
17 Jan 24
Prospectus supplement for primary offering
7:18pm
8-K
EX-10.1
joqrni9e0 0tndi6pu9t
16 Jan 24
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
5:18pm
8-K
k8m55mz
16 Jan 24
Vaxart, Inc. Announces Management Change
9:19am
8-K
EX-99.1
99pdsxjy 3gj
6 Sep 23
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
4:43pm
8-K
q86i80nsf2i3zr8d
26 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:20pm
8-K
EX-99.1
v7euvrywrhcfb7l9qis
10 Jul 23
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
4:12pm
8-K
EX-1.1
v88ueticu8
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm
8-K
EX-99.1
4s6sb2zn632
6 Jun 23
No Vaccine Related Serious Adverse Events (SAEs) reported to date
8:07am